Quantcast
Home > Quotes > SGYP
SGYP

Synergy Pharmaceuticals, Inc. Common Stock (DE) (SGYP) Quote & Summary Data

$1.82
*  
0.07
4%
Get SGYP Alerts
*Delayed - data as of Aug. 16, 2018  -  Find a broker to begin trading SGYP now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
3
Today's High / Low
$ 1.83 / $ 1.73
Share Volume
1,592,513
50 Day Avg. Daily Volume
2,895,852
Previous Close
$ 1.75
52 Week High / Low
$ 3.57 / $ 1.425
Market Cap
449,067,499
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -0.65
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.84

Intraday Chart

Shares Traded

Share Volume:
1,592,513
50 Day Avg. Daily Volume:
2,895,852

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.65

Trading Range

The current last sale of $1.82 is 27.72% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.83 $ 3.57
 Low: $ 1.73 $ 1.425

Company Description (as filed with the SEC)

Unless the context requires otherwise, the words "Synergy," "the Company," "we," "us," refer to Synergy Pharmaceuticals Inc. and, where appropriate, our subsidiaries. TRULANCE┬« is a trademark of Synergy Pharmaceuticals Inc. Any other trademarks reference in this Form 10-K are the property of their respective owners. All rights reserved. Business Overview Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. We have pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. We discovered and own 100% worldwide rights to our proprietary uroguanylin based GI platform which includes one commercial product and one development stage compound.  ... More ...  


Risk Grade

Where does SGYP fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.75
Open Date:
Aug. 16, 2018
Close Price:
$ 1.75
Close Date:
Aug. 16, 2018

Consensus Recommendation

Analyst Info